Abstract Objective: To assess antibody level as a test of autonomic failure (AF) associated with ganglionic nicotinic acetylcholine receptor antibody (AChR-Ab) autoimmunity. Patients and Methods: We searched the Mayo Clinic laboratory database of 926 ganglionic AChRAbeseropositive patients seen at our institution between October 1, 1997, and April 1, 2015, for initial level of 0.05 nmol/L or higher and contemporaneous autonomic reflex screen (standardized evaluation of adrenergic, cardiovagal, and sudomotor functions) from which Composite Autonomic Scoring Scale (CASS) scores could be calculated. Results: Of 289 patients who met inclusion criteria, 163 (56.4%) were women, median age was 54 years (range, 10-87 years), median antibody level was 0.11 nmol/L (range, 0.05-22.10 nmol/L), and median CASS total score was 2.0 (range, 0-10). Using receiver operating characteristic curve analysis, a level above 0.40 nmol/L predicted severe AF (CASS score, !7) with 92% specificity and 56% sensitivity. For at least moderate AF (CASS score !4 and anhidrosis !25%), a level of at least 0.20 nmol/L had 80% specificity and 59% sensitivity. Levels below 0.20 nmol/L were not predictive of the presence or absence of AF. For predicting orthostatic hypotension, ganglionic AChR-Ab level had excellent specificity above 0.4 nmol/L but lacked sensitivity. Autoantibodies to additional targets were present in 61 patients (21.1%). Conclusion: Ganglionic AChR-Ab level of at least 0.40 nmol/L is a moderately sensitive and highly specific marker for severe AF, as is a level of at least 0.20 nmol/L for moderate AF if CASS score is coupled with anhidrosis of 25% or more, among patients with suspected ganglionic AChR-Ab autoimmune autonomic ganglionopathy. Antibody levels of less than 0.20 nmol/L have little clinical importance in the absence of clinical AF.
A utoimmune autonomic ganglionopathy (AAG) is an antibody-mediated disease that classically manifests with widespread autonomic failure (AF) involving sympathetic, parasympathetic, and enteric functions. [1] [2] [3] One target of the pathogenic antibodies is the a3 subunit of the ganglionic nicotinic acetylcholine receptor antibody (AChR-Ab) in autonomic ganglia. 4 More severe AF has been found to occur with higher a3-AChR-Ab (ganglionic AChR-Ab; ganglionic Ab) level. 3, 5 In single case reports and small series, limited phenotypes with milder autonomic dysfunction have also been described, including isolated gastrointestinal dysmotility, 6 postural tachycardia syndrome, 7 pure AF, 8 distal small fiber neuropathy, 7 chronic idiopathic anhidrosis, 7 cognitive impairment, 9, 10 psychiatric symptoms, 11 and QT prolongation and ventricular tachycardia. 12 It has also been reported that many patients harboring antibodies against the ganglionic AChR-Ab have neither dysautonomia nor neurologic disease. 13 Limited AAG phenotypes generally are associated with lower ganglionic AChR-Ab levels, although it remains unclear if a strict correlation exists between level and severity or distribution of autonomic dysfunction. With the widespread availability and ordering of this test, a key question is whether low antibody levels are meaningful. The goal of the current study was to determine what an abnormal ganglionic AChR-Ab antibody means and when it is reliably associated with AF. We sought to correlate, in the first large cohort with detailed autonomic testing, the degree of AF associated with ganglionic antibody level.
PATIENTS AND METHODS
This study was approved by the Institutional Review Board of Mayo Clinic, Rochester, Minnesota (IRB 14-009546).
Study Population
The Mayo Clinic Rochester Neuroimmunology Laboratory database was queried for serum samples that contained ganglionic AChR-Ab at a level of 0.05 nmol/L or greater ("positive") from patients seen between October 1, 1997, and April 1, 2015. Patients were excluded if there was no autonomic reflex screen (ARS) within 1 month in the Mayo Clinic Rochester Autonomic Laboratory database or if the level from their earliest sample was less than 0.05 nmol/L (only the initial level was used for analysis if multiple samples were available from a single patient). The indication for testing ganglionic AChR-Ab, which is included in a service paraneoplastic autoantibody panel, was not used for screening eligible patients, nor was the reason for performing the ARS.
Autoantibody Measurements
A radioimmunoprecipitation assay was used to detect autoantibodies binding to the a3 subunit of the acetylcholine receptor, as previously described.
14 Testing for this a3-AChRAb, referred to as ganglionic AChR-Ab in this article, is most often performed in our neuroimmunology laboratory as part of a paraneoplastic autoimmunity profile screening for neuronal nuclear or cytoplasmic antibodies (including amphiphysin antibody; antineuronal nuclear antibody types 1, 2, and 3; Purkinje cell 1, 2, and Tr antibodies; collapsin response mediator protein 5 antibody; antiglial or neuronal nuclear antibody; and glutamic acid decarboxylase isoform 65 antibody), neuronal voltage-gated cation channel antibodies (P/Q-and N-type calcium channel antibodies and potassium channel complex antibody), striational antibodies, and muscle (a1) nicotinic AChR-Ab, as previously described.
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Autonomic Testing
The quantitative sudomotor axon reflex test was used to evaluate postganglionic sympathetic sudomotor nerves at 4 routine sites (forearm, proximal leg, distal leg, and foot). Control values were derived from studies on 357 healthy individuals aged 10 to 83 years. 19 For patients with autonomic testing later than 2010, quantitative sudomotor axon reflex test (Q-Sweat; WR Medical Electronics Co., Maplewood, MN) was used. Heart rate variation to deep breathing and the Valsalva ratio were used to quantify cardiovagal function, with results compared with normative data from 376 (heart rate response to deep breathing) and 425 (Valsalva ratio) healthy subjects aged 10 to 83 years. 19 Blood pressure and heart rate responses to the Valsalva maneuver and head-up tilt were used to examine cardiovascular adrenergic function. 20 Together, these tests constitute the ARS. Sudomotor function was also assessed with the thermoregulatory sweat test (TST), from which the distribution and percentage of anterior body surface anhidrosis was determined. 21 The Composite Autonomic Scoring Scale (CASS) quantifies severity and distribution of AF from the ARS. 22 The 10-point CASS total score is the sum of 3 subdomains: sudomotor (CASS-sudomotor range, 0-3), cardiovagal (CASS-cardiovagal range, 0-3), and adrenergic (CASS-adrenergic range, 0-4). Higher CASS scores indicate more severe AF. Each score is normalized for the confounding effects of age and sex. 19 The percent anhidrosis on TST also grades severity of sudomotor failure. One of the authors (J.K.C.-G.) reviewed all ARS and TST data and assigned CASS scores. Moderate AF was defined as a CASS score of 4 through 6 or TST anhidrosis of 25% to 50%, and severe AF was defined as a CASS score of 7 or higher or TST anhidrosis of 50% or more. Orthostatic hypotension (OH) was defined as a decrease in systolic blood pressure of 30 mm Hg or more or mean blood pressure decrease of 20 mm Hg or more during head-up tilt.
Statistical Analyses
We used Spearman rank correlation analysis to test the correlation between ganglionic AChR-Ab level and various measures of AF, including CASS total score and subdomain scores, presence of OH, and percent anhidrosis on TST. We then used receiver operator characteristic (ROC) curves to assess the sensitivity and specificity of ganglionic AChR-Ab level for moderate AF, severe AF, and OH.
RESULTS
Patients and Autoantibody Levels
Of 926 serum samples positive for ganglionic AChR-Ab, 637 were excluded for lack of contemporaneous ARS or because they were not the patient's initial sample, leaving 289 patients for analysis (Supplemental Figure Table 1) . Additional antibodies were sought in all patients and discovered in 61 (21.1%), most often at low level against glutamic acid decarboxylase antibody directed against the 65-kD isoform, skeletal muscle antigens, or voltage-gated calcium or potassium channels (Supplemental Table, available online  at http://www.mayoclinicproceedings.org). Ganglionic AChR-Ab level was not correlated with the presence of additional antibodies (P¼.25; Spearman r À0.068). These additional autoantibodies were present at low level and similar frequency in patients with low or high levels of ganglionic AChR-Ab; voltagegated potassium channel and collapsin response mediator protein 5 antibodies were only found in patients with low levels of ganglionic AChR-Ab. Eleven patients had multiple coexisting autoantibodies.
Autonomic Failure
By design, all 289 patients had undergone ARS that allowed CASS scoring of autonomic impairment. Patients' CASS total scores ranged from 0 to 10, with a median of 2.0, corresponding to only mild AF. Similarly, CASS subdomain scores ranged from normal to severe AF: CASS sudomotor range 0 to 3 (median, 1.0), CASS cardiovagal range 0 to 3 (median, 0.0), and CASS adrenergic range 0 to 4 (median 0.0) ( Table 1) . Visual inspection of CASS total and all subdomain scores suggested that high ganglionic AChR-Ab level was associated with high scores (severe AF), but low levels could be associated with the full spectrum from no autonomic impairment to severe AF ( Figure 1) ; this inspection helped guide our selection of statistical tests. Orthostatic hypotension was detected in 61 patients, among whom ganglionic AChR-Ab levels ranged from 0.05 to 22.1 nmol/L (median, 0.14 nmol/L). Most patients (175 [61.0%]) also had TST as part of the initial evaluation. The percent anhidrosis spanned the full range from 0% to 100%, with a median 2.0% (Table 1) .
Spearman Rank Analysis
Statistically significant correlations existed between increasing ganglionic AChR-Ab level and increasing CASS scores, including CASS total score (P¼.02) and all 3 subdomains (sudomotor, P¼.04; cardiovagal, P¼.003; adrenergic, P¼.02). Correlations were also significant between level and OH (P¼.001) and percent anhidrosis on TST (P¼.005). The Spearman coefficients for all of these correlations were poor (<0.25 in all cases; Table 2 ).
ROC Curve Analysis
The ROC curve analysis illustrated that a ganglionic AChR-Ab level of at least 0.40 nmol/L predicted severe AF (CASS score !7) with 92% specificity and 56% sensitivity. With severe AF defined as the combination of a CASS score of 7 or higher and anhidrosis of 50% or more, specificity remained high at 88%, and sensitivity improved to 65% (Figure 2, A) . Lower levels were less specific, and higher levels lost sensitivity without significant gains in specificity (Table 3 ). For at least moderate AF defined as a CASS score of 4 or higher, a level of at least 0.20 nmol/L had 81% specificity but only 36% sensitivity. The specificity was essentially the same (80%) and sensitivity was somewhat improved (59%) by incorporating percent anhidrosis (moderate AF as defined by a CASS score of 4 or higher and anhidrosis of 25% or more; Figure 2 , B). Levels of less than 0.20 nmol/L were not predictive of the presence or absence of AF (Table 3) . For predicting OH, ganglionic AChR-Ab level had excellent specificity above 0.40 nmol/L but lacked sensitivity (Table 3 , Figure 2 , C).
DISCUSSION
The key finding of this study is that a ganglionic AChR-Ab level of at least 0.40 nmol/L is a moderately sensitive and highly specific test for severe AF. It is similarly sensitive and specific at 0.20 nmol/L for moderate AF if an additional requirement of anhidrosis of 25% or more on TST is imposed, likely reflecting the importance of cholinergic failure with this antibody. It is even more sensitive but utterly nonspecific at 0.10 nmol/L for severe AF, highly specific but insensitive at 0.20 nmol/L for OH, and a very poor test for mild or moderate autonomic impairment at any value. The importance of low ganglionic AChR-Ab level is dictated by clinical context. Hence, a level of at least 0.40 nmol/L in a patient with suspected AAG is predictive of AAG with severe AF. Higher antibody levels were generally associated with more severe autonomic failure, but there were exceptions. Occasional high levels (>1.00 nmol/L) were seen in patients with no or only mild autonomic impairment, and several patients with severe autonomic failure had low levels (<0.20 nmol/L). The strengths of this study are its large size and the detailed autonomic testing performed in every patient. Previous studies of AAG relied on clinical phenotypes or included relatively few patients. 3, 8, [23] [24] [25] [26] [27] [28] A previous large retrospective study from our institution included 155 patients seropositive for ganglionic AChR-Ab (many of whom are included in the present study), but detailed autonomic testing was not reported. 13 Our study confirms prior reports associating higher levels of AChR-Ab with more severe AF. 3, 5, 8, 13, 25, 29, 30 This correlation was observed in all 3 subdomains of the CASS scoredadrenergic, cardiovagal, and sudomotordand reflects the presence of the ganglionic AChR-Ab in all types of autonomic ganglia. 31 Our study and that of Li et al 30 also found that high ganglionic AChR-Ab level is not required for severe AF (ie, low levels can be associated with more than mild or moderate autonomic impairment). This distinction from earlier reports is likely due to the different methods of case ascertainment. Whereas others have started with patients with the clinical phenotype of AAG and then documented the presence of ganglionic AChR-Ab (not surprisingly at high levels), we started with serum samples harboring the antibody of interest and then correlated the levels with the results of autonomic tests. Our approach likely underestimates the value of the test. For patients with low levels of antibody and severe AF, there is often a good clinical explanation. In our study, 9 patients had severe AF (high CASS score) despite low ganglionic AChR-Ab levels (<0.10 nmol/ L). Most of these patients had another explanation for AF (2 postinfectious autonomic neuropathy, 1 each of diabetes and familial amyloid, 1 with multiple system atrophy). We did not examine the change in ganglionic AChR-Ab level after treatment, which has previously been reported to reflect disease activity. 9, 23, 24, 32, 33 The presence of additional autoantibodies in a minority (21.1%) of ganglionic AChRAbeseropositive patients suggests that ganglionic AChR-Ab may sometimes be a nonspecific marker of autoimmunity. This possibility is further supported by the finding of ganglionic AChR-Ab at low levels in patients with myasthenia gravis 4 or celiac disease 34 without autonomic symptoms and in 14% of patients in the previous Mayo study who had autoimmune neurologic or systemic disorders without autonomic impairment. 13 Low levels of ganglionic AChR-Ab were present in patients with celiac disease but no autonomic symptoms except sicca complex. 34 Low positive antibody values (ganglionic AChR-Ab and other antibodies detected by radioimmunoprecipitation assays) can be detected in some patients with cancer but no neurologic disease or may be detected as false-positives in patients with monoclonal or polyclonal hypergammaglobulinemia. 13, 35 It is also possible that in some cases other autoantibodies have pathogenic relevance to autonomic dysfunction. Kimpinski et al The chief limitation of our study is that the CASS score does not capture many of the prominent symptoms of AAG, including sicca complex, pupil dysfunction, gastrointestinal tract dysmotility, or urinary retention. Sandroni et al 37 previously reported that abnormal pupillary responses, dry eyes and mouth, and lower gastrointestinal tract symptoms were all more likely in ganglionic AChRAbeseropositive than AChR-Abeseronegative patients when AAG was defined by clinical phenotype. Nevertheless, the CASS score is a validated measure of AF that summarizes several of the most commonly used clinical autonomic tests that are used to diagnose and measure treatment response in AAG. Because AAG phenotype is typically characterized as generalized AF, the CASS score should provide a reasonable index of AF. Another limitation of our study is that tests of sensitivity/specificity were applied only to the prespecified conditions of the study. 
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